ARWR:NSD-Arrowhead Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 57.02

Change

-3.37 (-5.58)%

Market Cap

USD 6.18B

Volume

1.95M

Average Target Price

USD 71.13 (+24.74%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD for treating liver diseases; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.60 (+0.74%)

USD56.30B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

+2.21 (+0.44%)

USD54.00B 20.76 16.02
MRNA Moderna, Inc

+10.62 (+10.78%)

USD39.00B N/A N/A
SGEN Seagen Inc

+0.82 (+0.50%)

USD29.47B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

-0.18 (-0.15%)

USD26.94B 28.36 26.40
RPRX Royalty Pharma plc

+1.39 (+3.51%)

USD24.75B 23.05 9.48
BNTX BioNTech SE

+3.09 (+3.03%)

USD24.53B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.98 (+3.11%)

USD23.81B N/A N/A
GMAB Genmab A/S

+0.68 (+1.93%)

USD23.24B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ARWR

Symbol Name Weight Mer Price(Change) Market Cap
EWMC Invesco S&P MidCap 400 Eq.. 0.00 % 0.40 %

-0.70 (-0.94%)

USD0.07B
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

+0.45 (+0.17%)

USD9.13B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+0.36 (+0.77%)

USD0.21B
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

+0.76 (+0.60%)

USD5.33B
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

+0.02 (+0.10%)

USD0.07B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.11% 43% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.11% 43% F 34% F
Trailing 12 Months  
Capital Gain -17.39% 33% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.39% 33% F 24% F
Trailing 5 Years  
Capital Gain 806.52% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 806.52% 96% A 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 148.30% N/A N/A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 148.30% N/A N/A 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 211.15% N/A N/A 4% F
Risk Adjusted Return 70.23% N/A N/A 83% B
Market Capitalization 6.18B 94% A 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 478.56 3% F 3% F
Price/Book Ratio 14.27 10% F 8% F
Price / Cash Flow Ratio 35.70 3% F 10% F
EV/EBITDA 739.74 2% F 2% F
Management Effectiveness  
Return on Equity -6.80% 91% A- 45% F
Return on Invested Capital 35.61% 95% A 96% A
Return on Assets -4.68% 91% A- 33% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.26 44% F 28% F
Short Percent 11.19% 30% F 20% F
Beta 1.74 37% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.